Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Editas Medicine (NQ: EDIT )

2.465 +0.095 (+4.01%)
Streaming Delayed Price Updated: 2:14 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Editas Medicine

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Second Sight Medical (NASDAQ:EYES) stock increased by 7.8% to $1.51 during Tuesday's pre-market session. The market value of their outstanding shares is at $59... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning! We've got another busy day ahead of us so let's get right into it with the biggest pre-market stock movers for Tuesday! 
Via InvestorPlace
21 Stocks Moving in Tuesday's Pre-Market Session
Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep. Also check out this: Moderna And 4 Other Stocks Sold By... 
Via Benzinga
Analyst Ratings For Editas Medicine
Within the last quarter, Editas Medicine (NASDAQ:EDIT) has observed the fo... 
Via Benzinga
Stock Market Rebound Fizzles Amid Hawkish Fed; Taiwan Semiconductor Breaks Out, JPMorgan Tumbles: Weekly Review
A rebound from Monday's lows faded, with the key indexes all down for the week. 
Via Investor's Business Daily
The Journey To Rewrite Human DNA Is About To Get Wild, Thanks To Pfizer, Bayer, Intellia And Other CRISPR stocks
Big Pharma is paying attention to CRISPR stocks. Could that alight shares this year? 
Via Investor's Business Daily
Pfizer Makes Foray Into CRISPR, Inking $1.35 Billion Deal With Beam Therapeutics
The companies hope to cure diseases of the liver, muscle and central nervous system. 
Via Investor's Business Daily
Top 5 Moonshots for 2022 Countdown: My No. 5 Pick
2021 wasn't the best year for gene-editing stocks, but expect a comeback in 2022. Here's the top gene-editing choice for next year. 
Via InvestorPlace
Stocks Hitting New 52-Week Lows Today
On Monday morning, 60 companies achieved new lows for the year. Points of Interest From Today's 52-Week Lows And Highs: Ginkgo Bioworks Holdings (NYSE:DNA) was... 
Via Benzinga
NES, WTTR: The Deal That Has Penny Stock Nuverra Environmental Solutions Skyrocketing Today
Nuverra Environmental (NES) stock is surging higher on Monday following news of a massive deal with Select Energy Services (WTTR). 
Via InvestorPlace
BLU Stock Alert: The Study Data That Has BELLUS Health Blasting Higher Today
BELLUS Health (BLU) stock is rocketing higher on Monday and it's all thanks to data from a Phase 2b clinical trial of BLU-5937. 
Via InvestorPlace
EDIT Stock: The Preclinical Data Sending Editas Medicine Rallying Today
After falling 60% year to date, EDIT stock is finally reversing course and trending higher in morning trading. 
Via InvestorPlace
22 Stocks Moving in Monday's Pre-Market Session
Gainers Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) rose 32.6% to $3.58 in pre-market trading after gaining more than 14% on Friday. Foghorn Therapeutics Inc. (NASDAQ: FHTX) rose... 
Via Benzinga
Looking for Growth in Small and Mid Cap Life Science Stocks
2021 is an unusual year for biotech with a “blow-off” February high in speculative small caps. 
Via Talk Markets
Editas Medicine, Inc (EDIT) Q3 2021 Earnings Call Transcript
EDIT earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Why Editas Medicine Stock Is Jumping Today
The gene-editing biotech company provided its Q3 update. 
Via The Motley Fool
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out... 
Via Benzinga
Should You Scoop Up Shares of This Promising Biotech on the Dip?
This gene-editing specialist could still be an excellent long-term play. 
Via The Motley Fool
The Daily Biotech Pulse: FDA Authorizes Moderna, J&J Booster Shots; Regulatory Approvals For Bristol-Myers Squibb, Sanofi-Regeneron; Ventyx IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CDC Committee Recommends Approval Of Merck, Pfizer's Pneumococcal Vaccine... 
Via Benzinga
Exposures Product Safety
Editas Medicine Could Skyrocket if Its Gene Editing Therapy Proves Successful
EDIT stock has been on a roller coaster this year, but it may be at an appealing price for speculative buyers who believe in its CRISPR tech. 
Via InvestorPlace
What's Hot in the Stock Market?
We've got a look at Merck and Amazon and Warby Parker and more. 
Via The Motley Fool
Exposures COVID-19
Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2021
Upgrades Maxim Group upgraded the previous rating for Indaptus Therapeutics Inc (NASDAQ: 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers ChemoCentryx (NASDAQ:CCXI) stock increased by 70.43% to $33.41 during Friday's regular session. As of 12:30 EST, this security is trading at a volume of 74.6... 
Via Benzinga
3 Spooky Healthcare Stocks I Would Avoid in October
Investors craving treats should look elsewhere this month. 
Via The Motley Fool
Editas Stock Firestorm Rages On; CRISPR Gene-Editing Stock Flashes Sell Signal
One of the leading CRISPR stock is under pressure on underwhelming data. 
Via Investor's Business Daily
52 Biggest Movers From Yesterday
Gainers Paltalk, Inc. (NASDAQ: PALT) shares jumped 60.1% to close at $8.39 on Wednesday. Smart Share Global Limited (NASDAQ: EM) jumped 36.2% to close at $3.91. Smart Share... 
Via Benzinga
EDIT Stock Is Plunging 20%. Here’s the Gene-Editing News Dragging It Down.
Today, investors in Editas Medicine and EDIT stock are pricing in some clinical trial results that are being viewed negatively by the market. 
Via InvestorPlace
PreMarket Prep Stock Of The Day: Editas Medicine
Benzinga's PreMarket Prep airs every morning from 8-9 a.m. ET. During that fast-paced, highly informative hour, traders and investors tune in to get the major news of the... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers NuCana (NASDAQ:NCNA) stock increased by 22.36% to $2.9 during Wednesday's regular session. The current volume of 77.9 million shares is 21650.59% of NuCana... 
Via Benzinga
Here's Why Editas Stock Dropped After Data From CRISPR-Based Retinal Disorder Candidate
Editas Medicine Inc (NASDAQ: EDIT) has announced initial clinical data from the ongoing Phase 1/2 BRILLIANCE trial of EDIT-101 for blindness due to Leber... 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.